22OCT

Sovereign AI unit backs Alphabet-owned lab

3 min read

16:30UTC

The UK Sovereign AI Unit joined Isomorphic Labs' $2.1bn Series B on 12 May, its third direct equity cheque in fifteen days and its first into a company majority-owned by a US technology giant.

← Back to Stryker agrees option to buy CMR Surgical Jump to analysis ↓

TechnologyDeveloping

Key takeaway

SAIU invested in an Alphabet-majority subsidiary, setting a sovereign eligibility precedent without any published ownership rule.

The UK Sovereign AI Unit (SAIU) joined Isomorphic Labs' $2.1bn Series B on 12 May 2026, according to a DSIT press release announcing the investment.⁠¹ The round was led by Thrive Capital, with Alphabet, GV (formerly Google Ventures, Alphabet's early-stage arm), CapitalG (Alphabet's growth equity fund), MGX (UAE), and Temasek (Singapore) also participating. Secretary of State Liz Kendall announced the cheque; investment size was withheld as commercially sensitive.

Isomorphic Labs was founded in 2021 by Sir Demis Hassabis, Nobel laureate and co-founder of DeepMind, as a spinout of DeepMind with Alphabet retaining majority control. The DSIT press release described the company as "British-founded and headquartered" and noted its "meaningful UK presence", without addressing the ownership structure or whether Alphabet's strategic control over intellectual property, geography, and exit decisions conflicts with the SAIU's stated purpose of strengthening UK ownership of Sovereign AI infrastructure.

Chi Onwurah MP (Shadow Science and Technology spokesperson) had placed the ownership question formally on record on 7 May: she wrote to DSIT minister Kanishka Narayan, describing DSIT's technology sovereignty strategy as incoherent. Five days later, the SAIU invested in a company whose controlling shareholder, Alphabet, was simultaneously co-investing via its own vehicles in the same round: UK sovereign capital sat alongside CapitalG and GV, both Alphabet instruments, in a single syndicate.

The SAIU has now made three direct equity investments: Callosum in April, Ineffable Intelligence at $1.1bn on 27 April, and Isomorphic on 12 May. DSIT has published no ownership threshold, sovereignty test, or eligibility criterion for SAIU equity. The Isomorphic investment therefore establishes by practice what no rule has yet established by design: majority-foreign-owned, UK-headquartered AI companies qualify for SAIU backing, including when the foreign controlling shareholder is a US technology conglomerate participating in the same round.

Deep Analysis

In plain English

The UK government has a programme called the Sovereign AI Unit (SAIU) that buys small stakes in British AI companies, with the aim of keeping cutting-edge AI technology under UK influence. On 12 May 2026, it made its third investment: buying a minority share in Isomorphic Labs, an AI company that uses artificial intelligence to design new medicines. The catch is that Isomorphic Labs is actually majority-owned by Alphabet, the American company that owns Google. So UK public money is going into a company where a US tech giant has the final say over strategy and decisions. The government called Isomorphic 'British-founded and headquartered', which is true, but that is different from British-controlled.

Deep Analysis

Root Causes

Three structural gaps created the SAIU's Isomorphic position. First, DSIT published no ownership threshold or eligibility criterion for SAIU equity before deploying capital, leaving definition-by-practice as the only operating rule.

Second, the UK lacks a deep-tech company at Isomorphic's scale that is both independent and domestically owned: the pipeline of genuinely Sovereign AI infrastructure companies tops out well below the $2.1bn round size.

Third, the political pressure to be seen co-investing in high-profile UK AI rounds outweighs the governance pressure to define 'sovereign' precisely, because the downside of missing a marquee $2.1bn deal is visible and immediate, while the downside of definitional incoherence is diffuse and deferred.

What could happen next?

Precedent
The Isomorphic investment sets a de facto SAIU eligibility rule: UK-headquartered companies with majority-foreign-controlling shareholders qualify for sovereign backing. Every subsequent SAIU deal will be judged against this precedent unless DSIT publishes an ownership threshold.
Immediate · 0.9
Risk
Chi Onwurah MP has the Isomorphic investment on parliamentary record as of 12 May. A Public Accounts Committee inquiry into SAIU deployment criteria is a plausible medium-term consequence if further Alphabet-adjacent investments follow.
Medium term · 0.6
Consequence
UK AI founders without Alphabet or major US corporate backing may face a higher bar for SAIU equity than the Isomorphic precedent suggests: the SAIU's three equity investments have all involved co-syndication with US institutional capital, not independent UK founders.
Short term · 0.7

Source Landscape

This story draws on mixed-leaning sources from United Kingdom (includes United Kingdom state media)

United Kingdom

Primary parallel: The UK Atomic Energy Authority's 1956 investment in ICL (International Computers Limited) as a minority shareholder alongside US technology principals offers the closest structural precedent. Britain held a meaningful equity stake and political relationship, but the technology roadmap was ultimately driven by US computing architecture and IBM compatibility requirements. UK sovereign capital bought visibility and a seat at the table; it did not buy control.

Counter-parallel: France's 2020 golden share mechanism in Renault gave the French state governance rights, including veto over asset disposals and key executive appointments, without majority equity. The SAIU holds no equivalent governance instrument in Isomorphic Labs; it holds only the financial return profile of a minority co-investor alongside Alphabet's own funds.

Isomorphic Labs operates in the AI drug-discovery segment where compute infrastructure costs create winner-takes-most dynamics. At $2.1bn Series B, the round implies a post-money valuation substantially above Alphabet's 2021 DeepMind spinout basis.

The SAIU's undisclosed cheque size, withheld as 'commercially sensitive', prevents any independent assessment of whether the implied return profile makes sense for public capital. For the NHS as a potential downstream customer of AI-designed medicines, an Alphabet-controlled Isomorphic creates a procurement dependency: UK public money has co-invested in a company whose IP the NHS may eventually need to licence from a US parent.

Consensus view: The Tony Blair Institute and Chatham House's Creon Butler assess that DSIT's framing of Isomorphic as 'British-founded and headquartered' conflates origin with control. Alphabet's majority stake means IP licensing terms, deployment geography, and exit decisions rest with Mountain View, not with the SAIU's minority position or with the UK government.

Counter-view: The Information Technology and Innovation Foundation in Washington argues the UK government's logic is defensible: strategic co-investment by a sovereign fund alongside Alphabet gives DSIT a board information right and a political relationship with a key AI infrastructure company, even without control. The precedent they cite is Norway's Government Pension Fund taking minority stakes in US tech equities without claiming governance.

Key tension: Whether a minority equity position in a majority-Alphabet company constitutes 'sovereign' backing in any meaningful operational sense, or whether it is a financial co-investment dressed in national-security language.

First Reported In

Update #4 · State capital lands on UK tech in nine days

GOV.UK / DSIT· 13 May 2026

Read original →

Causes and effects

Caused by

SAIU names seven firms in first cohort

SAIU's Isomorphic equity is its third direct cheque, following the seven-company first cohort named in April 2026 (ID:2693) which established the equity instrument.

Occurred 16 Apr 2026

Read story →

Ineffable lands $1.1bn seed, SAIU rides minority

SAIU's Ineffable Intelligence seed cheque (ID:2955) was the second direct equity; Isomorphic is the third, each extending the practice without published eligibility criteria.

Occurred 27 Apr 2026

Read story →

This Event

Sovereign AI unit backs Alphabet-owned lab

The investment sets a de facto eligibility precedent for UK sovereign capital entering majority-foreign-owned companies, without any published ownership threshold or eligibility rule from DSIT.

Led to

Orbital's $50m raise has no UK lead

Isomorphic Labs' $2.1bn Series B (ID:3275) was the second ex-DeepMind mega-round with no UK institutional lead; Orbital's $50m is the third, confirming a structural pattern.

Occurred 28 May 2026

Read story →

Different Perspectives

Abu Dhabi Investment Council

The Abu Dhabi Investment Council holds notes in Nscale's $3.36bn pre-IPO raise, beside Third Point, Apollo, Citadel and Nvidia. No British institution appears among the named holders of notes that convert into shares at Nscale's New York listing.

CDP Venture Capital

CDP Venture Capital, the venture arm of Italy's state lender, led TrueLayer's £20.4m round to expand Pay by Bank across Europe. A foreign state investor set the terms on a London fintech round in the same month the British Business Bank mostly followed.

EDBI

Singapore's state investor EDBI joined Universal Quantum's Series A of more than $100m, and the Sussex company is opening its first research centre outside Europe in Singapore. British state money is absent from the largest Series A by a UK quantum company.

Forbion

Forbion co-led OMass Therapeutics' $310m Series C with Bain Capital Life Sciences and Novo Holdings, while the British Business Bank and Syncona followed. The terms of the Oxford spinout's round were set by investors from three countries, none of them Britain.

British Business Bank

The Bank committed £180m to six AI funds on 15 October with no UK-deployment condition, yet led the first close of Microbiotica's £36m Series C. That lead, with Airtel Money choosing London for its £5.3bn debut, is the evidence that British money and markets still set some terms.

Stryker Corporation

Stryker called its roughly $400m CMR Surgical deal its entry into soft-tissue robotics, taking US sales rights for Versius, a board seat and an exclusive option over 100% of the company. The option lets Stryker choose whether and when a Cambridge robot maker becomes part of an American group.

Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Editorial standards.